A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home 2013 June
formats

Aleva Neurotherapeutic’s Ultra-Flexible Electrode Arrays for DBS

Aleva Neurotherapeutics is a spinoff of the Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory.   Aleva is developing unique microfabricated devices to more specifically target deep-brain stimulation. kurtzweilai.net recently published an interesting blog about the technology.  From the post: “Miniature, ultra-flexible electrodes could be the answer to more successful treatment for Parkinson’s diseases, according to Professor

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Aleva Neurotherapeutic’s Ultra-Flexible Electrode Arrays for DBS  comments 
formats

Mainstay Medical’s Reactiv8 to Treat LBP Caused by Arthrogenic Muscle Inhibition

Mainstay Medical was founded in 2008 by entrepreneur Dr. Danny Sachs. The company’s ReActiv8 neurostimulator is intended to treat chronic low back pain caused by arthrogenic muscle inhibition.  This is a neuroprotective condition in which the brain reflexively attempts to limit motor stimulation and movement in muscles surrounding a joint in response to damage or

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Mainstay Medical’s Reactiv8 to Treat LBP Caused by Arthrogenic Muscle Inhibition  comments 
formats

Neuros Medical’s Altius™ High Frequency Electrical Nerve Block™ Pain Therapy

Neuros Medical, a Cleveland, Ohio based neuromodulation company, developed the Altius implantable system to deliver Electrical Nerve Block therapy for the treatment of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post surgical pain, and chronic migraine.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Neuros Medical’s Altius™ High Frequency Electrical Nerve Block™ Pain Therapy  comments 
formats

Medtronic Issues Urgent Class-I Recall Notifications for the SynchroMed® Implantable Infusion System

Medtronic’s press release: MINNEAPOLIS – June 26, 2013 – In June 2013, Medtronic, Inc. (NYSE: MDT) initiated four medical device notifications to customers worldwide about the SynchroMed® Implantable Infusion System. These notifications provide clinicians with information to help identify and manage issues that impact the safe and reliable delivery of therapy using the SynchroMed Implantable

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Medtronic Issues Urgent Class-I Recall Notifications for the SynchroMed® Implantable Infusion System  comments 
formats

St Jude Receives CE Mark for Quadra Assura MP™ Multipoint CRT-D

St. Jude Medical today announced CE Mark approval of its next-generation quadripolar device, the Quadra Assura MP™ cardiac resynchronization therapy defibrillator (CRT-D). The device features MultiPoint™ Pacing (MPP) technology that enables physicians to pace multiple locations on the left side of the heart. This gives the clinician more choices to best optimize cardiac resynchronization therapy (CRT)

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St Jude Receives CE Mark for Quadra Assura MP™ Multipoint CRT-D  comments 
formats

Sorin Launches Reply 200 Pacemakers with Sleep Apnea Monitoring

Sorin announced today CE mark approval and the European commercial launch of the REPLY ™ 200 family of pacemakers featuring Sleep Apnea Monitoring (SAM).  According to the press release: Sleep apnea is highly prevalent and vastly undiagnosed in pacemaker patients. It increases the mortality risk and the risk of common cardiovascular co-morbidities such as hypertension, atrial

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Sorin Launches Reply 200 Pacemakers with Sleep Apnea Monitoring  comments 
formats

Boston Scientific Begins Patient Enrollment in U.S. Clinical Trial of Vercise™ DBS for Parkinson’s Disease, Presents EU Data

Boston Scientific announced today the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise DBS System for the treatment of Parkinson’s disease. 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Begins Patient Enrollment in U.S. Clinical Trial of Vercise™ DBS for Parkinson’s Disease, Presents EU Data  comments 
formats

Implantabe Preterm Labor Monitor

Not new, but recently came across while researching some information about related devices… The NASA Tech Briefs of May 1999 described a device that telemeters pressure changes to detect intrauterine contractions.  According to the brief: A biotelemetric system for monitoring key physiological parameters of a fetus and its uterine environment is undergoing development. The main

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Implantabe Preterm Labor Monitor  comments 
formats

IEEE Summer School on Implantable Devices – Bogotá, Colombia (July 9 – 12, 2013)

I have been honored with an invitation to present at the  Fourth IEEE CASS Summer School on Wearable and Implantable Biomedical Circuits and Systems in Bogotá, Colombia (July 9 – 12, 2013). I will be giving two 1 hour and 20 minute talks on “A Practical Perspective on Developing Novel Commercial Active Implantable Medical Devices”. 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on IEEE Summer School on Implantable Devices – Bogotá, Colombia (July 9 – 12, 2013)  comments 
formats

FDA Publishes Draft Guidance on Medical Device Cybersecurity

FDA has published a draft of the guidance document that it has developed to assist industry by identifying issues related to cybersecurity that manufacturers should consider in preparing premarket submissions for medical devices.  This guidance document is intended to supplement FDA’s “Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices” and

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on FDA Publishes Draft Guidance on Medical Device Cybersecurity  comments 
formats

Neurotech’s ADNS-300 Rechargeable Vagus Nerve Stimulator IPG for Epilepsy

In June 2012 Neurotech s.a. (http://www.neurotech-int.eu), a Belgium based developer and manufacturer of neurostimulation devices, obtained the CE Mark for its ADNS-300 system for the treatment of refractory epilepsy. According to the press release: “Advens therapy” uses the ADNS-300 stimulator as a therapeutic option for those patients who are refractory to anti-epileptic drugs and are not

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Neurotech’s ADNS-300 Rechargeable Vagus Nerve Stimulator IPG for Epilepsy  comments 
formats

FDA Approves St. Jude’s Ellipse™ and SJM Assura™ Portfolio of ICDs and CRT-D Devices

St. Jude Medical announced FDA approval of its next-generation Ellipse™ and SJM Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery. According to the announcement: The Ellipse and SJM Assura family of devices

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on FDA Approves St. Jude’s Ellipse™ and SJM Assura™ Portfolio of ICDs and CRT-D Devices  comments 
formats

St. Jude Medical Signs $40M Equity Investment and $300M Option with Spinal Modulation

St. Jude Medical and privately-held Spinal Modulation, Inc., today announced that they have entered into a series of agreements under which St. Jude Medical made a $40 million equity investment in Spinal Modulation, a company that has developed an innovative neuromodulation therapy that provides a new pain management option for patients with chronic, intractable pain.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude Medical Signs $40M Equity Investment and $300M Option with Spinal Modulation  comments